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experimental model, with serotype 9 causing
severe, serotype 3 mild, and serotype 1 intermedi-
ate inﬂammation [5]. Clearly, the experimental
settingof the present studydiffers greatly from that
of the rabbit meningitis model, and it is also
possible that the difference in timing of measure-
ment may account for the differences in results.
When the relative importance of complement and
serotype-speciﬁc antibodies was evaluated, com-
plement was shown to be a prerequisite for an
oxidative burst, whereas even low levels of sero-
type-speciﬁc antibodymay be sufﬁcient to produce
an oxidative burst in neutrophils.
In conclusion, the inﬂammatory response in
human adult blood caused by the four different
serotypes of S. pneumoniaewas similar with regard
to oxidative burst, neutrophil expression of
CD11b ⁄CD18, and production of pro-inﬂamma-
tory cytokines such as TNF-a, IL-6 and IL-8,
although there was a trend towards higher con-
centrations of IL-6 induced by the serotypes shown
previously to induce severe inﬂammation (9V and
23F). Thus, the results of the present study do not
conﬁrm previous suggestions that different sero-
types of S. pneumoniae can cause different degrees
of inﬂammatory response in humans.
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ABSTRACT
Ninety-six Streptococcus pneumoniae strains isolated
between January 1989 and December 2000 from
usually sterile sites of children aged < 5 years of age
were included in the study. Resistance to penicillin
(38.6% intermediate, 10.4% high-level), cefotax-
ime (20.8%), tetracycline (41.7%), chlorampheni-
col (33.3%) and erythromycin (27.1%), as well as
serogroup ⁄ type, were related to age and pathol-
ogy. Strains from children aged < 2 years showed
the highest penicillin resistance rate. Resistance to
penicillin, tetracycline, chloramphenicol and ery-
thromycinwas themost commonpattern (18.8% of
strains). Most isolates (80.2%) belonged to sero-
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Drug-resistant Streptococcus pneumoniae strains
continue to spread worldwide [1], mainly among
infants and young children. Some countries,
namely South Africa, Spain and Hungary, have
higher resistance rates than others [2], which may
result in a therapeutic problem. The distribution
of serotypes depends on the country [3], and
some serotypes are more prevalent in young
children than in adults [4]. The recent introduc-
tion of heptavalent conjugate pneumococcal vac-
cine makes it possible to prevent the disease in
children aged < 2 years old, so epidemiological
knowledge of both antibiotic resistance and
serotypes is of interest for our country and others
in which this vaccine is not included in current
vaccination programmes.
Ninety-six pneumococcal strains (those that
survived freezing) isolated from usually sterile
sites of children aged £ 5 years during the 12-year
period from January 1989 to December 2000 were
included in the present study. All strains were
frozen at ) 70 C in skimmed milk after identiﬁ-
cation (Gram’s stain and optochin growth inhibi-
tion) and antimicrobial susceptibility testing, and
thawed later for further susceptibility and typing
studies. All strains were screened initially for
susceptibility to penicillin (1-lg oxacillin disk),
chloramphenicol and erythromycin (Kirby–Bauer
technique) on Mueller–Hinton agar plates supple-
mented with sheep blood 5% v/v and incubated
in CO2 5% v/v. Later, MICs of penicillin, cefotax-
ime, chloramphenicol, tetracycline and erythro-
mycin were determined by the agar dilution
technique, according to the criteria of the National
Committee for Clinical Laboratory Standards
(NCCLS) [5]. S. pneumoniae ATCCR 49619 was
used as a control. Serotyping was carried out by
the Quellung reaction, with the use of 46 antisera
provided by the Statens Serum Institut (Copenha-
gen, Denmark). Both MICs and serotypes were
determined annually at the National Pneumococ-
cus Reference Centre.
Statistical analysis of all data was based on chi-
square tests. A difference between groups was
considered to have signiﬁcance when p was
< 0.05, with one degree of freedom and risk a
was 0.05.
Sixty-one (63.5%) strains were isolated from
children aged < 2 years. The focus or the main site
of the invasive infection was respiratory in 51
cases (31 aged < 2 years), meningeal in 20 (11 aged
< 2 years), osteoarticular in ten (seven aged < 2
years), cutaneous in four (two aged < 2 years), and
unknown in 11 (ten aged < 2 years).
As shown in Table 1, 47 (48.9%) strains were
non-susceptible to penicillin. Age was not statis-
tically signiﬁcant with regard to degree of resist-
ance, although a high proportion of children aged
< 2 years had diminished penicillin susceptibility
compared to those aged 2–5 years (54.1% vs.
40%). Isolates causing respiratory pathology were
those with the lowest resistance rate (38%), while
osteoarticular isolates had the highest resistance
rate (90%); this difference was statistically sig-
niﬁcant (p < 0.005).
Nineteen strains had a cefotaxime MIC of
1 mg ⁄L, one strain had an MIC of 2 mg ⁄L, and
the remaining 76 strains were susceptible to this
b-lactam. The cefotaxime MIC was equal to or one
dilution below that of penicillin, except in six
strains, whose cefotaxime MIC was one dilution
above that of penicillin.
Table 1. Resistance patterns according to penicillin MICs
of non-susceptible strains
No. of strains
No. of strains with penicillin
MIC (mg ⁄ L)
0.125 0.25 0.5 1 2
P 14 5 6 3
T 3
C 2
E 1
PT 1 1
PC 1 1
TC 4
TE 3
PCE 1 1
PTC 8 2 4 2
PTE 4 2 1 1
PCTE 18 1 2 5 5 5
S 36
P, resistant to penicillin; T, resistant to tetracycline; C,
resistant to chloramphenicol; E, resistant to erythromycin;
S, susceptible to all antibiotics tested.
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Rates of resistance to tetracycline (41.7%),
chloramphenicol (33.3%) and erythromycin
(27.1%) were lower than those for penicillin.
The erythromycin MIC for resistant strains was
‡ 128 mg ⁄L for all except two strains, which had
erythromycin MICs of 8 mg ⁄L and 64 mg ⁄L.
There were 12 different resistance patterns,
seven of them including penicillin, and 62.5% of
strains were resistant to one or more antibiotics
(70.2% of these had some degree of penicillin
resistance). Resistance to penicillin, tetracycline,
chloramphenicol and erythromycin (PTCE) was
present in 18.8% of strains. Apparently, the
degree of penicillin resistance, in terms of MIC,
was not related to multiresistance.
Nineteen serotypes distributed into 15 sero-
groups were present in our series (Table 2).
Seventy-seven (80.2%) of the 96 strains, including
100% of those with some degree of penicillin
resistance and 83.3% of those isolated from
children aged < 2 years, belonged to serotypes
related antigenically to those included in the
heptavalent conjugate vaccine. Resistant strains
were restricted to ﬁve serogroups, all included in
the seven-valent vaccine. More than half (57.9%)
of the 19 strains whose serotype was not included
in the seven-valent vaccine belonged to serotypes
1 and 5, and 26.3% of non-vaccine strains (sero-
types 5, 7, 12 and 24) had some degree of
resistance to penicillin, tetracyclines, or chloram-
phenicol; they came from children aged < 2 years,
and were agents of respiratory infections, except
for one cerebrospinal ﬂuid isolate.
One of the risk factors for an increase in penicil-
lin-resistant andmultiresistant S. pneumoniae is age
[6], and the high rate of antibiotic resistance of
pneumococci obtained from our paediatric
patients has been described previously [7–9]. The
source of isolates and the type of infection are also
related to the degree of antibiotic susceptibility
[10], with strains producing localised infections
expected to bemore resistant than invasive strains.
The prevalence of intermediate resistance is also
recognised generally [11], as is the high percentage
of resistant strains in children aged < 2 years [12].
Our ﬁnding of lower resistance rates in isolates
causing respiratory pathologywith respect to other
invasive isolates contrasts with the idea of higher
resistance in local respiratory infections [11]. The
ability of serogroup 18 and otherminor susceptible
serotypes to produce generalised respiratory infec-
tions from a local focus could explain this situation.
Although found in the USA [13], highly cefotax-
ime-resistant strains with intermediate resistance
to penicillin do not constitute a major problem in
Spain [14]. Spain was considered to be the focus of
chloramphenicol resistance [15], with rates > 40%,
a percentage that diminished during the 1990s,
especially in blood strains [10]. Our incidence of
33.3% is still higher than that of countries such as
the USA, where chloramphenicol resistance has an
incidence of 8.3% [11]. Tetracycline resistance
varies over time and in different parts of the world
[12,15] as a result of different patterns of drug use
[16]. The data presented here show a high percent-
age of resistance, but this is clearly lower than
reported in previous publications [7,8]. In contrast
with North America [17], erythromycin resistance
of pneumococci in Spain is caused mainly by
ribosomal changes. This is suggested by the fact
that all but one of our isolates had erythromycin
MICs ‡ 64 mg ⁄L. Some studies in Spain [10,12]
quote a higher prevalence of erythromycin resist-
ance in children than in adults, aswell as a growing
resistance trend, probably associated with trends
in antibiotic use.
The multiresistance pattern PTCE is a major
cause of concern, mainly because of its continuous
increase. Nearly a ﬁfth (18.8%) of pneumococci in
the series showed this resistance pattern, compared
with 12.5% found in all Spanish strains received at
the National Reference Centre during 1990–96 [18].
The serotype distribution of the isolates is similar
to that in the USA [4] or Europe [10], but contrasts
with that of oriental countries [3]. The distribution
of penicillin-susceptible and -resistant strains
among serotypes is also consistent with other
descriptions [2,19], as is the generalised penicillin
susceptibility of strains not included in the seven-
valent conjugate vaccine. The fact that all non-
vaccine strains resistant to any antibiotic were
isolated from children aged <2 years suffering from
respiratory infectionsmay be amatter of concern in
cases of severe respiratory infections of young
infants caused by one of these serotypes, even if
they were correctly vaccinated. Although our
health authorities have recommended pneumococ-
cal capsular vaccine for risk populations [20],
nothing is yet stipulated regarding conjugated
vaccine for infants and young children. The excel-
lent in-vitro coverage of heptavalent conjugate
vaccine suggests that its implementation in vaccin-
ation programmes could lower the incidence of
invasive disease during the ﬁrst 2–5 years of life in
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ourzone.According to thesedata, and thoseof other
Spanish and European studies [12], a nine-valent
vaccine, including serotypes 1 and 5, could be of
interest in Spain, as it would increase coverage of
children aged < 5 years from 80.2% to 91.7%.
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ABSTRACT
The prevalence of dengue antibodies was deter-
mined in the Attapeu region of South Laos with
225 blood samples collected from mostly febrile
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